Episode

Episode 193: Intensive BP lowering, elinzanetant for VMS, HTN in pregnancy and prostate CA screening

Podcast
Primary Care Update
Published
Nov 12, 2025
Duration seconds
2292
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/primary-care-update/episodes/Episode-193-Intensive-BP-lowering--elinzanetant-for-VMS--HTN-in-pregnancy-and-prostate-CA-screening-e3arcdb
Audio
https://anchor.fm/s/5693a5c/podcast/play/111046507/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2025-10-11%2Fc5045e3a-d847-7392-d117-2688afd9d4da.mp3
JSON
/v1/public/podcasts/primary-care-update-1000928/episodes/episode-193-intensive-bp-lowering-elinzanetant-for-vms-htn-in-pregnancy-and-prostate-ca-screening
Markdown
/podcast/primary-care-update-1000928/episode-193-intensive-bp-lowering-elinzanetant-for-vms-htn-in-pregnancy-and-prostate-ca-screening.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/primary-care-update-1000928/episodes/episode-193-intensive-bp-lowering-elinzanetant-for-vms-htn-in-pregnancy-and-prostate-ca-screening/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/primary-care-update-1000928/episode-193-intensive-bp-lowering-elinzanetant-for-vms-htn-in-pregnancy-and-prostate-ca-screening.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Primary care physicians Gary Ferenchick, Kate Rowland, Henry Barry and Mark Ebell want you to know about 4 new studies: the best choice of pharmacotherapy in hypertensive disorders of pregnancy, benefits and harms of intensive BP lowering, elinzanetant for therapy-induced vasomotor symptoms in women with breast cancer, and 23 year follow up of the European Prostate Cancer Screening Trial. Plus a confusing quiz question (thanks Gary!). Links Essential Evidence Plus: www.essentialevidenceplus.com HTN in pregnancy: https://pubmed.ncbi.nlm.nih.gov/40216176/ Intensive BP lowering: https://pubmed.ncbi.nlm.nih.gov/40902616/ Elinzanetant for vasomotor symptoms in patients taking tamoxifen or anastrozole: https://pubmed.ncbi.nlm.nih.gov/40454634/ 23 year follow-up of large European prostate cancer study: https://pubmed.ncbi.nlm.nih.gov/41160819/